论文部分内容阅读
目的:探讨沙利度胺(反应停)联合化疗治疗多发性骨髓瘤(MM)的疗效及不良反应。方法:16例MM患者接受沙利度胺联合常规MP方案或VAD方案化疗3个疗程。以骨髓浆细胞和M蛋白比例、血红蛋白、血尿素氮、血钙等定量作为治疗前后观察指标。结果:部分缓解10例,有效4例,无效2例,总有效率为87.5%。常见不良反应为皮疹、便秘、嗜睡、乏力、头昏、四肢麻木和下肢水肿等。结论:沙利度胺联合化疗方案治疗MM反应率高,不良反应少,耐受性好。
Objective: To investigate the efficacy and adverse reactions of thalidomide combined with chemotherapy in the treatment of multiple myeloma (MM). Methods: Sixteen patients with MM received 3 courses of thalidomide combined with conventional MP or VAD chemotherapy. Bone marrow plasma cells and M protein ratio, hemoglobin, blood urea nitrogen, serum calcium and other quantitative indicators before and after treatment. Results: Partial remission in 10 cases, effective in 4 cases, ineffective in 2 cases, the total effective rate was 87.5%. Common adverse reactions are rash, constipation, lethargy, fatigue, dizziness, numbness and lower extremity edema. Conclusion: The thalidomide combined with chemotherapy regimen has high MM response rate, few side effects and good tolerance.